


AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound represented by the formula



wherein

ring A is an optionally substituted 5- to 10-membered aromatic ring;

one of R¹ and R² are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group is an optionally substituted phenyl group and the other is an optionally substituted C₁₋₁₀ alkyl group;

both X and Y are the same or different and each is a bond, bonds; and -O-, S-, SO-, SO₂- or NR³- (R³ is a hydrogen atom or an optionally substituted hydrocarbon group); and

L is a divalent hydrocarbon C₁₋₁₀ alkylene group, or a salt thereof.

2. (Original) The compound of claim 1, wherein the 5- to 10-membered aromatic ring for ring A is a benzene ring.

3. (Original) The compound of claim 1, wherein the ring A is a 5- to 10-membered aromatic ring optionally having 1 to 3 substituents selected from
(1) a halogen atom;

- (2) a nitro group;
- (3) a cyano group;
- (4) an alkylendioxy group having 1 to 3 carbon atoms;
- (5) an alkyl group having 1 to 10 carbon atoms or an alkenyl group having 2 to 10 carbon atoms, each optionally having 1 to 3 substituents selected from a halogen atom, a hydroxy group, a carboxyl group, an alkoxycarbonyl group having 2 to 8 carbon atoms, a carbamoyl group, a cyano group, an amino group, an alkylcarbonylamino group having 2 to 8 carbon atoms, an alkoxycarbonylamino group having 2 to 8 carbon atoms and an alkylsulfonylamino group having 1 to 8 carbon atoms;
- (6) an optionally substituted hydroxy group;
- (7) an acyl group;
- (8) an optionally substituted amino group;
- (9) an optionally substituted cycloalkyl group having 3 to 10 carbon atoms;
- (10) an aryl group having 6 to 14 carbon atoms;
- (11) an optionally substituted thiol group;
- (12) an optionally substituted heterocyclic group; and
- (13) an amidino group.

4. (Original) The compound of claim 1, wherein R¹ is an alkyl group having 1 to 10 carbon atoms which is optionally substituted by a cycloalkyl group having 3 to 10 carbon atoms.

5-7. (Cancelled)

8. (Currently amended) The compound of claim 1, wherein R² is an alkyl group having 1 to 10 carbon atoms, ~~an aryl or a phenyl group having 6 to 14 carbon atoms or an aralkyl group having 7 to 13 carbon atoms~~, each optionally having 1 to 3 substituents selected from halogen atom, hydroxy group, nitro group, amino group, optionally halogenated alkyl group having 1 to 6 carbon atoms, alkoxy group having 1 to 6 carbon atoms, aromatic heterocyclic group and cycloalkyl group having 3 to 10 carbon atoms.

9. (Currently amended) The compound of claim 1, which is (2E)-3-[3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl]acrylamide;
5-{{3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl}oxy}pentanoic acid;
4-[3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl]piperazin-2-one; or
1-[3-(aminomethyl)-2-isobutyl-4-(4-methylphenyl)quinolin-6-yl]piperazine-2,5-dione;
or a salt thereof.

10. (Currently amended) A pharmaceutical composition agent comprising a compound of claim 1 ~~or a prodrug thereof~~ and a pharmacologically acceptable carrier.

11. (Currently amended) The pharmaceutical composition agent of claim 10, which is a ~~prophylactic or therapeutic~~ composition for agent of diabetes.

12. (Currently amended) The pharmaceutical composition agent of claim 10, which is a ~~prophylactic or therapeutic~~ composition for agent of diabetic complications.

13. (Currently amended) The pharmaceutical composition agent of claim 10, which is a ~~prophylactic or therapeutic~~ composition for agent of impaired glucose tolerance.

14. (Currently amended) The pharmaceutical composition agent of claim 10, which is a ~~prophylactic or therapeutic~~ composition for agent of obesity.

15-16. (Cancelled)

17. (Currently amended) A method for the ~~prophylaxis or~~ treatment of diabetes in a mammal, which comprises administering a compound of claim 1 ~~or a prodrug thereof~~ to the mammal.

18. (Currently amended) A method for the ~~prophylaxis or~~ treatment of diabetic complications in a mammal, which comprises administering a compound of claim 1 ~~or a prodrug thereof~~ to the mammal.

19. (Currently amended) A method for the ~~prophylaxis or~~ treatment of impaired glucose tolerance in a mammal, which comprises administering a compound of claim 1 ~~or a prodrug thereof~~ to the mammal.

20. (Currently amended) A method for the ~~prophylaxis or~~ treatment of obesity in a mammal, which comprises administering a compound of claim 1 ~~or a prodrug thereof~~ to the mammal.

21-28. (Cancelled)